The purpose of this study is to investigate novel treatments to delay progression to dementia in people with mild cognitive impairment (MCI) and metabolic syndrome (MS). The hypothesis is that treatment with pioglitazone or endurance exercise training will improve, stabilize, or attenuate decline in cognitive function compared to controls.
|Min Age||Max Age||Gender||Healthy Volunteers|
Accepts Healthy Volunteers
Recent evidence has linked metabolic syndrome (MS) with cognitive impairment and dementia, including Alzheimer's disease (AD). AD is often preceded by mild cognitive impairment (MCI), characterized by memory impairment but no functional impairment.The conversion rate from MCI to AD is about 15 percent per year, or 5 to 10 times that of cognitively normal individuals.
The mechanism(s) linking MS and cognitive impairment are not clear, although there is evidence that insulin resistance and inflammation play key roles. Thiazolidinediones (TZDs), medications approved for the treatment of Type 2 diabetes, reduce insulin resistance and have anti-inflammatory properties. A recent pilot study showed improvements in some areas of cognition in people with MCI or mild AD who were treated with the TZD rosiglitazone.
Endurance exercise training (EET) is an established treatment for MS and insulin resistance. There is also evidence that EET may improve cognitive function as well.
In this study, participants with both MS and MCI will be randomized to a 6-month intervention with treatment with pioglitazone, endurance exercise training, or a placebo and no exercise. The hypothesis is that treatment with pioglitazone or EET will improve cognitive function compared to controls, as evidenced by either improvement, stabilization, or lesser decline in performance on cognitive testing.
|Map Marker||City||State||Zip Code||Status||Primary Contact|
Geolocation is 39.7503186, -104.8367063
National Institute on Aging (NIA)
Robert S. Schwartz, MD
University of Colorado, Denver
Erica Borresen, BS